The risk of arteriosclerotic cardiovascular disease（ASCVD） in patients with type 2 diabetes mellitus（T2DM） is significantly higher than that in non-diabetic patients. Abnormal lipid metabolism and abnormal glucose metabolism are risk factors and pathogen－esis of ASCVD. The sodium-glucose cotransporter-2 inhibitor（SGLT-2i） is a new type of hypoglycemic agent excreting glucose via kidneys. Recent large clinical trials have shown that SGLT-2i shows significant cardiovascular and kidney benefits，but its mechanism remains unclear. This article reviewed effects of SGLT-2 inhibition on lipid metabolism in T2DM and analyzed its possible relation－ship with above protective effects.